Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
80 hedge funds and large institutions have $465M invested in Crinetics Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 11 closing their positions.
8% more capital invested
Capital invested by funds: $429M → $465M (+$36M)
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
0.92% more ownership
Funds ownership: 92.42% → 93.35% (+0.92%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 85 → 80 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$8.52M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.41M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.91M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1,000K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$867K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.96M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.46M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.89M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$661K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$497K |
CRNX Hedge Fund Activity: Q1 2021 in Review
80 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2021, worth a combined $465M — up 8.4% from $429M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CRNX and 6 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 27 added.
The largest buyer was Driehaus Capital Management, adding an estimated $8.52M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.96M sold.
- 80 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2021, down from 85 in Q4 2020.
- Funds reported $465M of Crinetics Pharmaceuticals stock for Q1 2021, up 8.4% quarter-over-quarter.
- 6 funds opened new Crinetics Pharmaceuticals positions in Q1 2021 and 11 closed out, a net change of -5 holders.
- The largest Crinetics Pharmaceuticals buyer in Q1 2021 was Driehaus Capital Management, an estimated $8.52M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2021 was RA Capital Management, an estimated $7.96M sold.
Based on aggregated 13F filings for Q1 2021.